Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced that it has acquired Ireland-based QUMAS, a leading global provider of Cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences and other highly regulated industries. The QUMAS acquisition further extends Accelrys’ informatics portfolio with the addition of mission-critical, end-to-end document and process management compliance solutions. Proven quality management solutions supported by robust content and business process management capabilities provided by QUMAS advance Accelrys’ ability to help customers better manage the scientific innovation lifecycle by reducing regulatory risks, lowering quality costs, improving compliance effectiveness and increasing operational efficiency in bringing new products to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62188-accelrys-acquires-compliance-and-quality-management-leader-qumas
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
http://www.Salessuccessconsulting.com - Boston Wordpress design and development services. Our team has experienced wordpress, PHP, HTML coders that are proficient to handle advanced wordpress customization and custom theme design. The business feels pleased to talk about a long list of persuaded customers who always favor Sales Success Consulting for their website and online marketing campaign associated obligations.
CHS Inc., the nation’s leading cooperative and a global energy, grains and foods company, is committed to continued growth that will drive economic value to its farmer owners and the rural communities in which they live, its leaders told attendees at its recent annual meeting.
“Our ultimate responsibility is to invent the CHS of the future by making the decisions, executing the investments and managing the financial health of this company in a manner that not only adds value for you today, but continues to pay off 10 and 20 years down the road,” CHS President and Chief Executive Officer Carl Casale told attendees. “Ultimately, it’s about taking actions today that will benefit tomorrow’s owner, the generations that are now playing in farm yards or buying their first blue FFA jackets.”
To view the Multimedia News Release, go to http://www.multivu.com/mnr/58034-chs-inc-putting-future-first-for-cooperative-farmer-owners
They were destined to find each other, to love each other. But when Dimitri is sentenced to death by silver Skyler makes a daring and dangerous trip into Lycan territory to save him. He is bound and cannot help her, for him it is a fate worse than death as his one true love, his lifemate, finds herself caught in a trap that can cost her her life. Christine Feehan’s much anticipated, epic love story Dark Wolf. http://www.ChristineFeehan.com Paranormal romance
America’s appetite for specialty foods hit a record high last year, with consumers spending $86 billion on everything from artisanal chocolates and cheese to olive oils and charcuterie. To help food enthusiasts navigate the wealth of food-gift choices available this holiday season, the Specialty Food Association today released the results of a survey that reveal the top product categories, flavors and ingredients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64542-specialty-food-association-survey-gluten-free-hot-trend-holiday-gifts
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
Santa is lactose intolerant, Mrs Santa had gastric bypass surgery. Both have smelly intestinal gas. Flat-D can save their marriage. Flat-D Innovations makes the Flatulence Deodorizer. It is an activated charcoal cloth pad that is placed in the underwear next to the buttocks to remove gas odor.
Moncler S.p.A. announces that today it has obtained approval from CONSOB for the Prospectus for the Initial Public Offering issued for the purpose of the admission of the Company’s ordinary shares to trading on the Mercato Telematico Azionario organized and managed by Borsa Italiana S.p.A..
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64154-Eurazeo-Moncler-IPO-clearance